[ad_1]
A clinical trial revealed that a vaccine to protect against common chlamydia against badually transmitted infections (STIs) is safe and has shown promising signs of effectiveness.
The researchers found that the vaccine elicited an immune response in preliminary trials of 35 healthy women.
Other tests will be done to determine if it can fully protect against infection, but experts say that it is an "important first step" in the fight against this disease.
"The results are encouraging as they show that the vaccine is safe and that it produces the kind of immune response likely to potentially protect against chlamydia," said Professor Robin Shattock, of the Imperial College of Medicine. London.
"The next step is to advance the vaccine for further testing, but until it is done, we will not know whether it is really protective or not."
Chlamydia is the most common bacterial STI in the world, with young adults being the most affected.
This can lead to infertility, as well as complications such as an ectopic pregnancy, arthritis and increased susceptibility to other STIs such as HIV.
The infection is currently treated with antibiotics, but people can still catch it again. Up to three quarters of the cases show no symptoms.
The study, led by Imperial College London and the Statens Serum Institute in Copenhagen, tested two different formulations of the vaccine to determine which would give better results.
Both formulations elicited an immune response in 100% of the participants – compared to the lack of immune response in those receiving a placebo – but one of them did show better performance. and produced more antibodies.
Experts hope that this formulation will undergo further clinical development.
The research, published in The Lancet Infectious Diseases, revealed that vaccines did not produce any serious side effects.
[ad_2]
Source link
